Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

od Dusselier, Matthieu, Deluche, Elise, Delacourt, Nellie, Ballouhey, Julia, Egenod, Thomas, Melloni, Boris, Vergnenègre, Charlotte, Veillon, Rémi, Vergnenègre, Alain
Izdano u PLoS One (2019)

Pneumatocoeles after bronchoscopic lung volume reduction with valves

od Lestelle, Francois, Fumat, Romane, Didier, Alain, Collot, Samia, Egenod, Thomas, Faviez, Guillaume, Hermant, Christophe, Plat, Gavin, Guibert, Nicolas
Izdano u ERJ Open Res (2021)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

od Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
Izdano u J Cachexia Sarcopenia Muscle (2019)

Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk

od Egenod, Thomas, Tricard, Jeremy, Fumat, Romane, Simonneau, Yannick, Favard, Florent, Guillot, Marc-Samir, Collot, Samia, Dupuis, Marion, Melloni, Boris, Vergnenegre, Alain, Guibert, Nicolas, Dusselier, Matthieu
Izdano u Int J Chron Obstruct Pulmon Dis (2021)

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

od Barlesi, Fabrice, Dixmier, Adrien, Debieuvre, Didier, Raspaud, Christophe, Auliac, Jean-Bernard, Benoit, Nicolas, Bombaron, Pierre, Moro-Sibilot, Denis, Audigier-Valette, Clarisse, Asselain, Bernard, Egenod, Thomas, Rabeau, Audrey, Fayette, Jérôme, Sanchez, Myriam Locatelli, Labourey, Jean-Luc, Westeel, Virginie, Lamoureux, Pauline, Cotte, François-Emery, Allan, Victoria, Daumont, Melinda, Dumanoir, Juliette, Reynaud, Dorothée, Calvet, Christophe Yannick, Ozan, Nicolas, Pérol, Maurice
Izdano u Oncoimmunology (2020)